文献速递急性肾损伤

癌症患者发生免疫检查点抑制剂相关急性肾损伤的实践模式与结局

Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI.
PubMed 文献 · Nephrol Dial Transplant · 2026-01-01

ICI治疗者发生AKI的风险显著低于非ICI系统治疗者(校正风险比0.80,95%CI 0.74-0.86,P<.0001)。发生AKI并停用ICI的587例中,54例(9%)在随后6个月内再次接受ICI,其中24例(44%)出现复发性AKI;再次接受ICI者的总生存优于接受其他非ICI系统治疗者(校正风险比0.38,95%CI 0.22-0.67,P<.001)。

要点

  • ICI组4年任何分期AKI粗发生率为29%,严重AKI(≥2期)为7%。
  • ICI治疗者发生AKI风险低于非ICI系统治疗者(校正风险比0.80,95%CI 0.74-0.86,P<.0001)。
  • 发生AKI并停用ICI者中再次接受ICI并不常见,但作者认为对部分患者可能值得考虑。

核心结论

  • 真实世界研究显示,接受ICI治疗的癌症患者发生严重AKI的风险为中等程度,低于接受其他系统抗癌治疗者。
  • 发生AKI并停用ICI的患者中再次接受ICI并不常见,但作者认为对部分患者可能值得考虑。

研究设计与样本

  • 以血清肌酐升高定义AKI并按事件严重程度分级,采用时间到事件模型比较AKI发生风险、易感因素与生存结局。

主要发现

  • 4380例接受ICI治疗的患者中,4年任何分期AKI粗发生率为29%,严重AKI(≥2期)为7%。
  • 与AKI风险升高相关的特征包括男性、泌尿生殖系统(相对于其他)恶性肿瘤、存在高血压、糖尿病或慢性肾脏病,以及使用非甾体抗炎药。
  • ICI治疗者发生AKI的风险显著低于非ICI系统治疗者(校正风险比0.80,95%CI 0.74-0.86,P<.0001)。
  • 发生AKI且30天内仍存活并停用ICI的587例中,54例(9%)在随后6个月内再次接受ICI,其中24例(44%)出现复发性AKI事件。
  • 再次接受ICI治疗者的总生存优于接受其他非ICI系统治疗者(校正风险比0.38,95%CI 0.22-0.67,P<.001)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Acute kidney injury (AKI) is a known immune-related adverse event of cancer immune checkpoint inhibitor (ICI) therapy. Further population-based data on AKI incidence, risk factors and practice patterns post-ICI therapy are needed. METHODS: We measured the cumulative incidence of AKI among advanced cancer patients while receiving ICI therapy and non-ICI systemic therapy in Ontario, Canada (2012-18). An increase in serum creatinine was used to define AKI and graded according to event severity. Time to event modeling was used to compare the risk of developing AKI, pre-disposing factors and survival outcomes. RESULTS: We studied 16 425 patients with advanced cancer receiving either ICI or non-ICI systemic therapy. Among 4380 patients receiving ICI therapy, the overall crude 4-year incidence of AKI (any stage) was 29% and severe AKI (stage ≥2) was 7%. Characteristics associated with a higher risk of AKI included male sex, genitourinary (versus other) malignancy, the presence of hypertension, diabetes or chronic kidney disease, and prescription of a non-steroidal anti-inflammatory drug. The risk of experiencing AKI was significantly lower among patients treated with ICI versus non-ICI systemic therapy [adjusted hazards ratio (aHR) 0.80, 95% confidence interval (CI) 0.74-0.86, P-value <.0001]. Among the 587 patients who experienced an AKI and were both alive and discontinued ICI therapy within 30 days, 54 (9%) were re-challenged with ICI in the following 6 months and 24 (44%) had a recurrent AKI event. Patients who were re-challenged with ICI therapy had improved overall survival as compared with patients that received other non-ICI systemic therapy (aHR 0.38, 95% CI 0.22-0.67, P-value <.001). CONCLUSION: Our real-world study demonstrates a modest risk for severe AKI among cancer patients receiving ICI therapy, lower than with exposure to other systemic cancer therapies. Among patients who developed AKI and stopped ICI therapy, re-challenge was uncommon but may warrant consideration for select patients.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Blanchette PS, Reid J, Richard L, et al. Practice patterns and outcomes in cancer patients developing immune checkpoint inhibitors-related AKI. Nephrol Dial Transplant. 2026. PMID: 41014247. doi:10.1093/ndt/gfaf191

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。